The short answer
A filler consent must name vascular occlusion explicitly and disclose its consequences: permanent blindness, skin necrosis and scarring, and rarely stroke. It must describe the warning signs, state that treatment with high-dose hyaluronidase is time-critical and most effective within hours, and make clear that reversal can fail and that non-hyaluronic-acid fillers cannot be dissolved at all. Omitting this is the most litigated gap in filler consent.
Why is this the most litigated omission?
Dermal fillers are FDA Class III devices approved through the premarket approval pathway, and the FDA's own patient-facing materials and its General Issues Panel meetings on dermal fillers identify unintentional intravascular injection as the most serious risk of the product class. When the regulator that approved the device names a catastrophic risk, a consent form that does not name it is difficult to defend.
The mechanism is straightforward and worth stating in the form itself. Filler injected into or compressing an artery blocks perfusion downstream. In the tissue, that produces ischemia and then necrosis. If the injected material travels retrograde into the ophthalmic circulation — the glabella, nasal dorsum, nasolabial fold and forehead are the recognized danger zones because branches there communicate with the ophthalmic artery — the result can be sudden, permanent vision loss. The literature also documents ophthalmoplegia, ptosis and cerebral infarction after facial filler injection.
Cross-sectional reviews of injectable filler litigation repeatedly find lack of informed consent pleaded alongside the injury itself. The plaintiff does not have to prove the injector was careless if they can prove they were never told this could happen.
What exactly has to appear in the form?
| Disclosure | Required content |
|---|---|
| The event | Vascular occlusion — filler entering or compressing a blood vessel |
| Blindness | Sudden, usually painful vision loss that is frequently permanent and not reliably reversible |
| Skin necrosis | Tissue death, ulceration and permanent scarring, most often nose, glabella, lips |
| Neurological injury | Rare stroke, ophthalmoplegia, ptosis |
| Warning signs | Immediate severe or disproportionate pain, blanching, dusky or mottled discoloration, visual change, headache |
| Time criticality | Emergency treatment is measured in hours, not days; delay worsens outcome |
| Hyaluronidase | High-dose hyaluronidase is the reversal agent for HA filler, may require repeated dosing, and can itself cause allergic reaction |
| Limits of reversal | Treatment may fail; non-HA fillers such as calcium hydroxylapatite, poly-L-lactic acid and PMMA are not dissolvable |
| Patient duty | Contact the clinic immediately, and the specific number to call after hours |
The hyaluronidase paragraph must be honest about limits. Published management protocols, including the high-dose pulsed hyaluronidase approach described by De Lorenzi, use large doses flooded through the ischemic territory, and experimental work indicates that intervention within roughly the first four hours materially improves outcomes. Saying reversal exists without saying it is time-limited and imperfect creates exactly the false expectation that generates a claim.
What has to be true in the treatment room?
Consent language is only defensible if the clinic can actually do what the form promises. That means hyaluronidase physically on site and in date at every session where HA filler is injected — not orderable, on site — a written vascular occlusion emergency protocol signed by the medical director, staff trained on it with dated competency records, an after-hours contact route the patient can actually reach, and a defined referral pathway to ophthalmology or emergency care.
Document the drill: the batch of hyaluronidase, its expiry, and the last date staff rehearsed the protocol. When a board reviews an occlusion case, the question is not only what the consent said but whether the practice was equipped to respond.
What this means for your paperwork
Your filler consent should carry vascular occlusion as its own headed section, not a bullet inside a list of bruising and swelling, and many practices have the patient initial that section separately. Pair it with a written aftercare card repeating the warning signs and the emergency number, because a patient who leaves with symptoms at 9 p.m. needs the information in their hand rather than in a signed file.
Keep the signed consent, the aftercare acknowledgement, the treatment record naming product, lot number, volume and injection sites, the hyaluronidase stock log, the signed emergency protocol, and staff training records together. That set is what an insurer requests within a day of an occlusion report.
Related questions
This answer is educational and is not legal or medical advice. Requirements vary by state and change over time — verify with your own legal and clinical advisors before applying anything here in practice.